ULURU Inc. Provides Altrazeal® Clinical Update

ADDISON, Texas, Nov. 10, 2010 /PRNewswire/ — ULURU Inc.
(NYSE Amex:
ULU) today provided a clinical update and summary of recent
participation at major wound care conferences.

During the past 45 days Altrazeal® has been presented at
three major wound care conferences

Symposium of Advanced Wound Care (“SAWC”) Clinical Symposium on
Advances in Skin and Wound Care (“CSASWC”) Diabetic Limb Salvage
2010 (“DLS”)

Participation in these conferences not only benefit our United
States sales and marketing activities but also our expansion into
international markets. This is of particular importance given that
Altrazeal® was recently granted CE Mark approval, which opens
potential pathways for commercialization in 27 European countries
and other international markets. The expansion of the clinical
evidence supporting Altrazeal® places the Company in a strong
position to make major headway in the commercialization of
Altrazeal® in the target markets.

At the SAWC and CSASWC out of the hundreds of scientific and
clinical poster presentations one in ten featured Altrazeal® or
Altrazeal®  in combination with other products. Of major
significance was the number of posters where wound care
professionals are using the properties of Altrazeal® to enhance
the benefits or improve the performance of other products. At
CSASWC there were 8 posters that presented Altrazeal® in
combination with 7 different products. Of these presentations,
numerous posters featured Altrazeal® securing skin substitutes
and managing wound exudate to enhance the performance of these
expensive products.

In addition to the poster presentations Altrazeal® was
featured at two workshops at CSASWC. Dr. Greg Bohn demonstrated
application techniques for numerous chronic wound types in a wound
care simulation workshop. Thi

‘/>”/>

SOURCE